An evaluation of 18F-BMS-986192 (anti-PD-1 adnectin) and 89Zr-Nivolumab (anti-PD-1 antibody) in 13 patients with NSCLC treated with nivolumab demonstrated that significantly higher radiopharmaceutical tumor uptake, as well as higher uptake in tumors that were positive for PD-1 and PD-L1 by IHC, was significantly correlated with response to treatment. Here, CD274 is linked to neoplasm.